Announcement • Jul 08
Kewaunee Scientific Corporation, Annual General Meeting, Aug 26, 2026 Kewaunee Scientific Corporation, Annual General Meeting, Aug 26, 2026. Recent Insider Transactions Derivative • Jul 02
President exercised options and sold US$1.2m worth of stock On the 30th of June, Thomas Hull exercised options to acquire 33k shares at no cost and sold these for an average price of US$36.25 per share. This trade did not impact their existing holding. For the year to April 2020, Thomas' total compensation was 24% salary and 76% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Thomas currently holds 33.00k shares (0.011496615466083243 of the company). Company insiders have collectively sold US$3.6m more than they bought, via options and on-market transactions in the last 12 months. Reported Earnings • Jun 28
Full year 2026 earnings released: EPS: US$3.36 (vs US$3.99 in FY 2025) Full year 2026 results: EPS: US$3.36 (down from US$3.99 in FY 2025). Revenue: US$282.0m (up 17% from FY 2025). Net income: US$9.62m (down 16% from FY 2025). Profit margin: 3.4% (down from 4.7% in FY 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has increased by 33% per year, which means it is tracking significantly ahead of earnings growth. New Risk • Jun 26
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: US$97.5m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks High level of debt (57% net debt to equity). Profit margins are more than 30% lower than last year (3.9% net profit margin). Market cap is less than US$100m (US$97.5m market cap). Announcement • Jun 11
Kewaunee Scientific Corporation to Report Q4, 2026 Results on Jun 23, 2026 Kewaunee Scientific Corporation announced that they will report Q4, 2026 results After-Market on Jun 23, 2026 Board Change • May 20
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 1 experienced director. 5 highly experienced directors. Director John Campbell was the last director to join the board, commencing their role in 2025. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Announcement • Feb 26
Kewaunee Scientific Corporation to Report Q3, 2026 Results on Mar 11, 2026 Kewaunee Scientific Corporation announced that they will report Q3, 2026 results After-Market on Mar 11, 2026 Announcement • Nov 27
Kewaunee Scientific Corporation to Report Q2, 2026 Results on Dec 10, 2025 Kewaunee Scientific Corporation announced that they will report Q2, 2026 results After-Market on Dec 10, 2025 Announcement • Sep 12
Kewaunee Scientific Corporation Announces Appointment of J. Jette Campbell to Board of Directors, Effective September 10, 2025 Kewaunee Scientific Corporation announced the appointment of J. Jette Campbell, CPA, to its Board of Directors, effective September 10, 2025. Mr. Campbell will hold office as a Class II director, for a term expiring at the Company's annual meeting of stockholders to be held in 2027 and thereafter until his successor has been duly elected and qualified or until his earlier death, removal or resignation. Mr. Campbell is a highly regarded advisor to lenders and business owners in the areas of financial restructuring, business strategy, and crisis management. Mr. Campbell has served as a partner at Carl Marks Advisors since January 2004. Mr. Campbell's engagements at Carl Marks Advisors have spanned a wide range of industries, including distribution, manufacturing, healthcare, education, real estate, and financial services, and Mr. Campbell has worked extensively in the building materials and furniture-manufacturing industries. Prior to joining Carl Marks Advisors, Mr. Campbell served as an executive at several large multinational firms including Griffin LLC, a DuPont agricultural chemical joint venture (CFO and Head of Corporate Development), PepsiCo (CFO, North European Snack Foods Division), and Frito-Lay (VP and Controller). Mr. Campbell is a certified public accountant and began his career in public accounting with Arthur Andersen & Co. in Houston, Texas. During a 17-year span, he was Partner in both Arthur Andersen & Co. and KPMG Peat Marwick. Mr. Campbell earned an undergraduate degree in business from Auburn University and engaged in post-graduate study at Auburn and Harvard Business School. He has an Honorary Doctorate from Paul Quinn College for his leadership of its executive committee. Announcement • Aug 28
Kewaunee Scientific Corporation to Report Q1, 2026 Results on Sep 10, 2025 Kewaunee Scientific Corporation announced that they will report Q1, 2026 results After-Market on Sep 10, 2025 Announcement • Jul 03
Kewaunee Scientific Corporation, Annual General Meeting, Aug 27, 2025 Kewaunee Scientific Corporation, Annual General Meeting, Aug 27, 2025. Announcement • Jun 12
Kewaunee Scientific Corporation to Report Q4, 2025 Results on Jun 25, 2025 Kewaunee Scientific Corporation announced that they will report Q4, 2025 results at 4:00 PM, US Eastern Standard Time on Jun 25, 2025 Announcement • Feb 27
Kewaunee Scientific Corporation to Report Q3, 2025 Results on Mar 12, 2025 Kewaunee Scientific Corporation announced that they will report Q3, 2025 results at 4:00 PM, US Eastern Standard Time on Mar 12, 2025 Announcement • Nov 28
Kewaunee Scientific Corporation to Report Q2, 2025 Results on Dec 11, 2024 Kewaunee Scientific Corporation announced that they will report Q2, 2025 results After-Market on Dec 11, 2024 Announcement • Aug 29
Kewaunee Scientific Corporation to Report Q1, 2025 Results on Sep 11, 2024 Kewaunee Scientific Corporation announced that they will report Q1, 2025 results at 4:00 PM, US Eastern Standard Time on Sep 11, 2024 Announcement • Jul 09
Kewaunee Scientific Corporation, Annual General Meeting, Aug 28, 2024 Kewaunee Scientific Corporation, Annual General Meeting, Aug 28, 2024. Announcement • Jun 15
Kewaunee Scientific Corporation to Report Q4, 2024 Results on Jun 26, 2024 Kewaunee Scientific Corporation announced that they will report Q4, 2024 results After-Market on Jun 26, 2024 Valuation Update With 7 Day Price Move • May 14
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to US$42.00, the stock trades at a trailing P/E ratio of 13.8x. Average trailing P/E is 37x in the Medical Equipment industry in the US. Total returns to shareholders of 243% over the past three years. Recent Insider Transactions • Mar 28
Vice President of Human Resources recently sold US$107k worth of stock On the 26th of March, Elizabeth Phillips sold around 3k shares on-market at roughly US$32.50 per share. This transaction amounted to 24% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth US$110k. Insiders have been net sellers, collectively disposing of US$416k more than they bought in the last 12 months. Recent Insider Transactions • Mar 17
Insider recently sold US$93k worth of stock On the 14th of March, Mandar Ranade sold around 3k shares on-market at roughly US$30.85 per share. This transaction amounted to 25% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of US$201k more than they bought in the last 12 months. Recent Insider Transactions Derivative • Mar 14
Insider notifies of intention to sell stock Douglas Batdorff intends to sell 4k shares in the next 90 days after lodging an Intent To Sell Form on the 13th of March. If the sale is conducted around the recent share price of US$31.11, it would amount to US$109k. Since June 2023, Douglas' direct individual holding has decreased from 10.57k shares to 9.67k. Company insiders have collectively sold US$521k more than they bought, via options and on-market transactions in the last 12 months. Reported Earnings • Mar 09
Third quarter 2024 earnings released: EPS: US$0.87 (vs US$0.26 in 3Q 2023) Third quarter 2024 results: EPS: US$0.87 (up from US$0.26 in 3Q 2023). Revenue: US$46.8m (down 23% from 3Q 2023). Net income: US$2.52m (up 249% from 3Q 2023). Profit margin: 5.4% (up from 1.2% in 3Q 2023). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 90% per year but the company’s share price has only increased by 33% per year, which means it is significantly lagging earnings growth. Announcement • Feb 22
Kewaunee Scientific Corporation to Report Q3, 2024 Results on Mar 06, 2024 Kewaunee Scientific Corporation announced that they will report Q3, 2024 results After-Market on Mar 06, 2024 Valuation Update With 7 Day Price Move • Dec 28
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to US$29.19, the stock trades at a trailing P/E ratio of 12.2x. Average trailing P/E is 37x in the Medical Equipment industry in the US. Total returns to shareholders of 133% over the past three years. Recent Insider Transactions • Dec 15
President recently sold US$137k worth of stock On the 13th of December, Thomas Hull sold around 6k shares on-market at roughly US$22.80 per share. This transaction amounted to 15% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Thomas has been a net seller over the last 12 months, reducing personal holdings by US$209k. Recent Insider Transactions Derivative • Dec 14
President notifies of intention to sell stock Thomas Hull intends to sell 5k shares in the next 90 days after lodging an Intent To Sell Form on the 12th of December. If the sale is conducted around the recent share price of US$22.79, it would amount to US$114k. For the year to April 2017, Thomas' total compensation was 40% salary and 60% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since March 2023, Thomas' direct individual holding has increased from 20.55k shares to 40.20k. Company insiders have collectively bought US$146k more than they sold, via options and on-market transactions, in the last 12 months. Valuation Update With 7 Day Price Move • Dec 13
Investor sentiment improves as stock rises 36% After last week's 36% share price gain to US$23.22, the stock trades at a trailing P/E ratio of 9.7x. Average trailing P/E is 36x in the Medical Equipment industry in the US. Total returns to shareholders of 137% over the past three years. New Risk • Dec 08
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 5.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (2.0% operating cash flow to total debt). Earnings have declined by 3.3% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (5.2% average weekly change). Shareholders have been diluted in the past year (2.6% increase in shares outstanding). Market cap is less than US$100m (US$51.2m market cap). Reported Earnings • Dec 07
Second quarter 2024 earnings released: EPS: US$0.94 (vs US$0.086 loss in 2Q 2023) Second quarter 2024 results: EPS: US$0.94 (up from US$0.086 loss in 2Q 2023). Revenue: US$50.4m (down 7.6% from 2Q 2023). Net income: US$2.73m (up US$2.98m from 2Q 2023). Profit margin: 5.4% (up from net loss in 2Q 2023). The move to profitability was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 68% per year but the company’s share price has only increased by 33% per year, which means it is significantly lagging earnings growth. Announcement • Nov 17
Kewaunee Scientific Corporation to Report Q2, 2024 Results on Dec 06, 2023 Kewaunee Scientific Corporation announced that they will report Q2, 2024 results at 4:00 PM, US Eastern Standard Time on Dec 06, 2023 Reported Earnings • Sep 01
First quarter 2024 earnings released: EPS: US$0.86 (vs US$0.27 loss in 1Q 2023) First quarter 2024 results: EPS: US$0.86 (up from US$0.27 loss in 1Q 2023). Revenue: US$49.8m (flat on 1Q 2023). Net income: US$2.47m (up US$3.22m from 1Q 2023). Profit margin: 5.0% (up from net loss in 1Q 2023). Over the last 3 years on average, earnings per share has increased by 45% per year but the company’s share price has only increased by 23% per year, which means it is significantly lagging earnings growth. Announcement • Jul 07
Kewaunee Scientific Corporation, Annual General Meeting, Aug 23, 2023 Kewaunee Scientific Corporation, Annual General Meeting, Aug 23, 2023, at 11:00 US Eastern Standard Time. Agenda: To elect three class i directors; to ratify the appointment of the independent registered public accounting firm of forvis, llp as the company’s independent auditors for fiscal year 2024; to approve, on an advisory basis, the compensation of company's named executive officers; to approve the kewaunee scientific corporation 2023 omnibus incentive plan; and to transact such other business as may properly come before the meeting. New Risk • Jul 06
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 3.2% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Earnings have declined by 43% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (3.2% increase in shares outstanding). Market cap is less than US$100m (US$45.4m market cap). Recent Insider Transactions Derivative • Jun 29
President exercised options and sold US$92k worth of stock On the 23rd of June, Thomas Hull exercised options to acquire 6k shares at no cost and sold these for an average price of US$16.47 per share. This trade did not impact their existing holding. For the year to April 2017, Thomas' total compensation was 43% salary and 57% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since June 2022, Thomas' direct individual holding has decreased from 24.06k shares to 19.56k. Company insiders have collectively bought US$283k more than they sold, via options and on-market transactions, in the last 12 months. New Risk • Jun 09
New minor risk - Insider selling There has been significant insider selling in the company's shares over the past 3 months. Total value of shares sold: US$71k This is considered a minor risk. There are several reasons why an insider may be selling, including to cover a tax obligation or pay for some other expense. However, we generally consider it a negative if insiders have been selling, especially if they do so below the current price. It implies that they considered a lower price to be reasonable. This is a weak signal, but if there is a pattern of unexplained selling, it can be a sign the insider believes the company's stock is overpriced. Note: We only include open market transactions and private dispositions of directly owned stock by individuals, not by corporations or trusts. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Earnings have declined by 52% per year over the past 5 years. Minor Risks Significant insider selling over the past 3 months (US$71k sold). Market cap is less than US$100m (US$45.3m market cap). Recent Insider Transactions • Mar 12
Insider recently bought US$657k worth of stock On the 8th of March, Anita Zucker bought around 39k shares on-market at roughly US$16.65 per share. This transaction amounted to 22% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought US$1.1m more in shares than they have sold in the last 12 months. Reported Earnings • Mar 09
Third quarter 2023 earnings released: EPS: US$0.26 (vs US$0.47 loss in 3Q 2022) Third quarter 2023 results: EPS: US$0.26 (up from US$0.47 loss in 3Q 2022). Revenue: US$60.8m (up 50% from 3Q 2022). Net income: US$723.0k (up US$2.04m from 3Q 2022). Profit margin: 1.2% (up from net loss in 3Q 2022). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has increased by 26% per year, which means it is tracking significantly ahead of earnings growth. Reported Earnings • Dec 08
Second quarter 2023 earnings released: US$0.086 loss per share (vs US$1.11 loss in 2Q 2022) Second quarter 2023 results: US$0.086 loss per share (improved from US$1.11 loss in 2Q 2022). Revenue: US$54.6m (up 40% from 2Q 2022). Net loss: US$243.0k (loss narrowed 92% from 2Q 2022). Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has only fallen by 4% per year, which means it has not declined as severely as earnings. Board Change • Nov 16
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 4 highly experienced directors. President, CEO & Director Thomas Hull was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Sep 09
First quarter 2023 earnings released: US$0.27 loss per share (vs US$0.48 loss in 1Q 2022) First quarter 2023 results: US$0.27 loss per share (improved from US$0.48 loss in 1Q 2022). Revenue: US$50.1m (up 27% from 1Q 2022). Net loss: US$747.0k (loss narrowed 45% from 1Q 2022). Over the last 3 years on average, earnings per share has fallen by 34% per year but the company’s share price has increased by 5% per year, which means it is well ahead of earnings. Reported Earnings • Jun 30
Full year 2022 earnings released: US$2.20 loss per share (vs US$1.33 loss in FY 2021) Full year 2022 results: US$2.20 loss per share (down from US$1.33 loss in FY 2021). Revenue: US$168.9m (up 14% from FY 2021). Net loss: US$6.13m (loss widened 67% from FY 2021). Over the last 3 years on average, earnings per share has fallen by 52% per year but the company’s share price has only fallen by 4% per year, which means it has not declined as severely as earnings. Recent Insider Transactions • May 18
Insider recently bought US$421k worth of stock On the 12th of May, Peter Kamin bought around 30k shares on-market at roughly US$14.05 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought US$529k more in shares than they have sold in the last 12 months. Board Change • Apr 28
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 4 highly experienced directors. President, CEO & Director Thomas Hull was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Board Change • Apr 02
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 4 highly experienced directors. President, CEO & Director Thomas Hull was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Mar 15
Third quarter 2022 earnings: EPS in line with expectations, revenues disappoint Third quarter 2022 results: US$0.47 loss per share (down from US$0.029 profit in 3Q 2021). Revenue: US$40.6m (up 22% from 3Q 2021). Net loss: US$1.32m (down US$1.40m from profit in 3Q 2021). Revenue missed analyst estimates by 2.8%. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 58 percentage points per year, which is a significant difference in performance. Reported Earnings • Sep 09
First quarter 2022 earnings released: US$0.48 loss per share (vs US$0.22 loss in 1Q 2021) The company reported a soft first quarter result with increased losses and weaker control over costs, although revenues improved. First quarter 2022 results: Revenue: US$39.5m (up 8.4% from 1Q 2021). Net loss: US$1.35m (loss widened 125% from 1Q 2021). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 66 percentage points per year, which is a significant difference in performance. Reported Earnings • Jul 10
Full year 2021 earnings released: US$1.33 loss per share (vs US$1.70 loss in FY 2020) The company reported a decent full year result with reduced losses and improved control over expenses, although revenues were flat. Full year 2021 results: Revenue: US$147.5m (flat on FY 2020). Net loss: US$3.67m (loss narrowed 22% from FY 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 72 percentage points per year, which is a significant difference in performance. Reported Earnings • Mar 12
Third quarter 2021 earnings released: EPS US$0.029 (vs US$0.70 loss in 3Q 2020) The company reported a decent third quarter result with improved earnings and profit margins, although revenues were weaker. Third quarter 2021 results: Revenue: US$33.3m (down 2.6% from 3Q 2020). Net income: US$81.0k (up US$2.00m from 3Q 2020). Profit margin: 0.2% (up from net loss in 3Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 78 percentage points per year, which is a significant difference in performance. Announcement • Feb 25
Kewaunee Scientific Corporation to Report Q3, 2021 Results on Mar 10, 2021 Kewaunee Scientific Corporation announced that they will report Q3, 2021 results After-Market on Mar 10, 2021 Is New 90 Day High Low • Feb 09
New 90-day high: US$13.37 The company is up 59% from its price of US$8.39 on 10 November 2020. The American market is up 14% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 7.0% over the same period. Is New 90 Day High Low • Jan 13
New 90-day high: US$12.56 The company is up 45% from its price of US$8.65 on 14 October 2020. The American market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 8.0% over the same period. Is New 90 Day High Low • Dec 16
New 90-day high: US$9.79 The company is up 8.0% from its price of US$9.10 on 16 September 2020. The American market is up 12% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Medical Equipment industry, which is up 7.0% over the same period. Reported Earnings • Dec 11
Second quarter 2021 earnings released: US$0.065 loss per share The company reported a decent second quarter result with reduced losses and improved control over expenses, although revenues were weaker. Second quarter 2021 results: Revenue: US$39.0m (down 1.8% from 2Q 2020). Net loss: US$180.0k (loss narrowed 92% from 2Q 2020). Over the last 3 years on average, earnings per share has fallen by 103% per year but the company’s share price has only fallen by 31% per year, which means it has not declined as severely as earnings. Is New 90 Day High Low • Nov 25
New 90-day high: US$9.75 The company is up 5.0% from its price of US$9.25 on 26 August 2020. The American market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 6.0% over the same period. Announcement • Nov 24
Kewaunee Scientific Corporation to Report Q2, 2021 Results on Dec 09, 2020 Kewaunee Scientific Corporation announced that they will report Q2, 2021 results at 5:00 PM, Eastern Standard Time on Dec 09, 2020 Is New 90 Day High Low • Oct 29
New 90-day low: US$8.33 The company is down 13% from its price of US$9.52 on 31 July 2020. The American market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 2.0% over the same period. Is New 90 Day High Low • Oct 07
New 90-day low: US$8.72 The company is down 8.0% from its price of US$9.50 on 09 July 2020. The American market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 12% over the same period. Announcement • Aug 28
Kewaunee Scientific Corporation to Report Q1, 2021 Results on Sep 08, 2020 Kewaunee Scientific Corporation announced that they will report Q1, 2021 results at 5:00 PM, Eastern Standard Time on Sep 08, 2020 Announcement • Jul 05
Kewaunee Scientific Corporation(NasdaqGM:KEQU) dropped from Russell Microcap Growth Index Kewaunee Scientific Corporation(NasdaqGM:KEQU) dropped from Russell Microcap Growth Index 
